Kalos Management’s Avita Medical RCEL Stock Holding History

Kalos Management’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-619	Closed	-$8.65K	–	315
2023 Q1	$8.65K	Buy	+619	New	+$6.59K	0.02%	225

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Kalos Management's RCEL Position: Q2 2023 in Review

Kalos Management sold out of Avita Medical (RCEL) in Q2 2023, closing a stake of 619 shares — an estimated $8.65K sold.

Kalos Management first reported a position in RCEL in Q1 2023 and held it in 1 quarter. The position peaked at $8.65K in Q1 2023. 80 funds tracked by Wall St. Rank hold RCEL as of Q2 2023.

Kalos Management reported no remaining Avita Medical position as of Q2 2023 after selling out during the quarter.
Kalos Management sold 619 Avita Medical shares in Q2 2023, an estimated $8.65K.
Kalos Management first reported a position in Avita Medical in Q1 2023 and held it in 1 quarter.
Kalos Management's Avita Medical position peaked at $8.65K in Q1 2023.
80 funds tracked by Wall St. Rank held Avita Medical as of Q2 2023.

Based on Kalos Management's 13F filing for Q2 2023, filed 9 Aug 2023.